Therapeutic Monoclonal Antibody Development for Breast Cancer
Our Services
Therapeutic monoclonal antibodies are key to advancing targeted approaches in breast cancer, providing precise mechanisms to address specific tumor markers and enhance therapeutic efficacy. With a robust track record in antibody development, Alfa Cytology is equipped to offer end-to-end services for monoclonal antibody development in breast cancer, covering everything from antigen discovery and antibody screening to preclinical validation and optimization.
Breast Cancer Therapeutic Antibodies
Therapeutic antibodies for breast cancer utilize diverse and sophisticated mechanisms to combat the disease. These strategies range from directly targeting and inhibiting tumor-promoting receptors like HER2, to enhancing cell-killing efficacy by delivering conjugated cytotoxic payloads, and even reinvigorating the body's own immune system to attack cancer cells by blocking checkpoints like PD-1/PD-L1.
Fig.1 Different types of monoclonal antibodies are used to treat breast cancer. (Eini, et al., 2021)
Targets in Breast Cancer
Key therapeutic targets in breast cancer, such as hormone receptors (ER/PR), HER2, and immune checkpoints (PD-1/PD-L1), are critical molecular drivers of the disease. Identifying these specific targets within a tumor is essential for guiding precision medicine and selecting the most effective, tailored therapies.
Workflow of Monoclonal Antibody Development
Targets Discovery & Validation
- Bio-layer Interferometry (BLI)
- ELISA
- Western Blotting
- Surface Plasmon Resonance (SPR)
Antigens Preparation
- Gene Cloning
- Refolding and Validation
- Expression
- Quality Control
- Protein Extraction and Purification
Antibody Development
- Hybridomas Technology
- Single B-Cell Technology
- Phage Antibody Library
- More
Purification of Antibody
- Gel Filtration Chromatography
- Affinity Chromatography
- Ion Exchange Chromatography
- Reverse Phase Chromatography
In Vitro Evaluation
- 2D Cell Lines
- Cell Cycle Analysis
- 3D Tumor Assays
- Migration and Invasion Analysis
- Cell Proliferation Analysis
- Apoptosis Analysis
In Vivo Evaluation
- Tumor Suppression Analysis
- Safety Assessment
- Survival Assessment
- More
Backed by specialized antibody discovery, engineering, and characterization platforms, Alfa Cytology provides rigorous, comprehensive preclinical support for monoclonal antibody development in breast cancer. For inquiries or to discuss a tailored study plan, please contact our team.
Reference
[1] EINI M, ZAINODINI N, MONTAZERI H, et al. A Review of Therapeutic Antibodies in Breast Cancer [J]. Journal of Pharmacy & Pharmaceutical Sciences, 2021, 24(3): 363-80.